Browse the evidence

Deletion of the endocannabinoid-synthesizing enzyme NAPE-PLD specifically in adipose tissue causes obesity, glucose intolerance, and insulin resistance in mice, primarily through impaired adipose browning and altered gut microbiota composition.

This research suggests that the health of your fat tissue is not passive. If the enzymes that produce certain signaling lipids (endocannabinoids) in your fat cells are disrupted, it can trigger a cascade leading to obesity and insulin resistance, partly by changing your gut bacteria. While this is a genetic mouse model, it highlights that metabolic health involves complex communication between fat, gut, and brain, not just food intake.

The metabolic phenotype caused by adipose NAPE-PLD deletion is mediated by changes in gut microbiota composition, as evidenced by the partial transfer of the obese and insulin-resistant phenotype to germ-free mice via fecal microbiota transplantation.

Your gut bacteria play a direct role in your body weight and insulin sensitivity. This study shows that the specific mix of bacteria in your gut can transmit metabolic health information to your fat tissue. While this is a mouse study, it suggests that supporting a healthy gut microbiome may be an important part of metabolic health strategies.

Alternative splicing of the p53 gene produces the p44 variant, which accelerates aging phenotypes, cognitive decline, and senescence by hyperactivating the IGF-1 pathway.

Current research focuses on molecular mechanisms; no direct human intervention is recommended based solely on this paper.

Progeria (HGPS) is caused by a splicing mutation in the LMNA gene producing progerin, which sequesters in the nuclear membrane and reduces SIRT1 activity, modeling vascular aging.

Understanding progeria mechanisms aids research into normal vascular aging.

Androstenedione supplements do not produce anabolic effects or strength improvements in eugonadal men, regardless of age or training status.

Do not rely on androstenedione supplements to build muscle. Studies show that even at 300mg daily combined with training, it does not increase strength more than placebo in either young or older men. The conversion to testosterone is too low to be effective.

Combining Endoscopic Gastric Remodeling (EGR) with a GLP-1 Receptor Agonist (GLP-1RA) initiated within 6 months of the procedure yields significantly greater weight loss (23.7% TWL) than EGR monotherapy or sequential therapy.

If you are considering Endoscopic Gastric Remodeling (EGR), ask about starting a GLP-1RA (like semaglutide or liraglutide) within 6 months of the procedure. This specific combination yields significantly better weight loss (approx. 24%) than either treatment alone. Avoid taking other types of weight loss medications for more than 6 months before the procedure, as this is associated with poorer outcomes.

Anti-obesity medication (AOM) administered in primary care settings produces approximately double the weight loss compared to lifestyle interventions alone, achieving an additional ~3 kg reduction.

If you are working with a primary care provider to lose weight, adding an FDA-approved anti-obesity medication to your lifestyle plan can roughly double your weight loss results compared to lifestyle changes alone. However, be prepared for the possibility that you may need to stay on the medication long-term to maintain the loss, as weight regain is common when stopping treatment.

Adjunctive semaglutide therapy significantly enhances total body weight loss and prevents post-balloon weight regain compared to intragastric balloon (IGB) alone in patients with BMI ≥ 27 kg/m².

If you are using an intragastric balloon for weight loss, adding semaglutide (a GLP-1 medication) can significantly increase your total weight loss and help you keep the weight off after the balloon is removed. The study used a specific dosing schedule starting at 0.5mg and going up to 1mg weekly, pausing while the balloon is in place, and restarting after removal. This approach helps overcome the natural weight regain that often happens after balloon removal alone.

A Very Low-Calorie Ketogenic Diet (VLCKD) induces rapid weight loss and improves metabolic parameters in obese patients by inducing physiological ketosis, which suppresses appetite and shifts metabolism toward fat oxidation while preserving lean mass.

To use VLCKD, restrict carbs to under 50g/day and calories to ~800/day for 8-12 weeks, using meal replacements and vegetables. This induces ketosis, which naturally suppresses hunger and burns fat while protecting muscle. You must supplement with electrolytes and vitamins. This is a medical therapy, not a casual diet, and requires monitoring. It is specifically for those with obesity and related health issues, not for everyone.

Higher protein quality (specifically higher leucine content and digestibility, measured by DIAAS) promotes greater resistance exercise-induced muscle hypertrophy compared to lower quality proteins when protein doses are not artificially elevated to saturation.

To maximize muscle growth from resistance training, prioritize high-quality proteins rich in leucine (like whey, eggs, or meat) over lower-quality sources (like some plant proteins) unless you are willing to consume significantly larger amounts of the lower-quality protein to hit the same leucine threshold. This is particularly important for older adults who need higher leucine doses to stimulate muscle synthesis.

Carbohydrate restriction, particularly very-low-carbohydrate (VLC) or ketogenic diets, significantly improves glycemic control (lower HbA1c), reduces insulin requirements, and stabilizes blood glucose profiles in patients with Type 1 Diabetes (T1D) compared to standard high-carbohydrate diets.

For T1D patients, adopting a very-low-carbohydrate diet (under 50g carbs/day) can significantly stabilize blood sugar and reduce the amount of insulin needed. This approach lowers the risk of both high and low blood sugar spikes. However, it requires careful medical supervision to safely reduce insulin doses and avoid hypoglycemia during the transition.

Anti-obesity medications (Liraglutide 3mg, Lorcaserin, Naltrexone/Bupropion, Phentermine/Topiramate) are effective for weight loss in type 2 diabetes when used as adjuncts to lifestyle changes.

If lifestyle changes aren't enough, ask about FDA-approved weight loss drugs like Lorcaserin or Naltrexone/Bupropion. They are safe for diabetics and work best when combined with diet and exercise. Note that if you don't lose at least 5% of your body weight in 3 months, doctors should stop the medication.

Pharmacologic management using GLP-1 receptor agonists (specifically liraglutide), topiramate, and phentermine/topiramate is effective for treating weight regain or weight loss plateaus following bariatric surgery.

If you are regaining weight after bariatric surgery, ask your provider about GLP-1 agonists (like liraglutide) or topiramate-based therapies. Current observational data supports their use for weight optimization in this specific population.

Combining beinaglutide (0.2 mg TID) with metformin (850 mg BID) produces significantly greater weight loss and improvements in insulin sensitivity and hyperandrogenism compared to metformin monotherapy in obese women with PCOS over a 12-week period.

For obese women with PCOS who are already taking metformin but struggling with weight loss or high androgens, adding beinaglutide (starting low and titrating up) is a clinically superior strategy to staying on metformin alone. This combination leads to significantly more weight loss, better waist circumference reduction, and improved insulin sensitivity. While it involves injections, the study found that side effects were manageable and did not cause more people to quit than those taking metformin alone. This approach is particularly relevant for those who have not achieved sufficient results with lifestyle changes and metformin monotherapy.

Intentional weight loss of 7–14% of initial body weight typically enables the discontinuation of anti-diabetic medications in overweight or obese patients with type 2 diabetes.

If you have type 2 diabetes and are overweight, losing 7-14% of your body weight through a structured program (diet, exercise, behavior change) can significantly reduce or eliminate your need for diabetes medications. This should be done under a doctor's supervision, as your medication doses will likely need to be adjusted as you lose weight.

Sibutramine combined with microcrystalline cellulose (Reduxin) produces clinically significant weight loss (average 20.0 kg over 12 months) and reduces waist circumference in patients with alimentary obesity and comorbidities.

For patients with obesity and comorbidities, a 12-month course of sibutramine (Reduxin) under medical supervision can result in significant weight loss (approx. 20kg) and waist reduction. Heart rate does not significantly increase with proper monitoring.

High-protein diets promote weight loss and fat mass reduction while maintaining fat-free mass by increasing energy expenditure through diet-induced thermogenesis and stimulating anorexigenic hormones.

Consider increasing your protein intake to help with weight loss and preserving muscle. This works by boosting your metabolism and reducing hunger hormones. It is one of several effective dietary strategies.

In patients with overweight or obesity without type 2 diabetes, 1-year treatment with semaglutide 2.4 mg or tirzepatide results in clinically meaningful weight loss of 14.1% and 16.5%, respectively, in real-world clinical practice.

If you have obesity or are overweight and do not have type 2 diabetes, treatment with semaglutide (Wegovy) or tirzepatide (Zepbound/Mounjaro) for one year in a real-world setting leads to significant weight loss, averaging 14-16% of body weight. This effectiveness holds true in routine clinical practice, not just in clinical trials, although reaching the maximum dose is not guaranteed for everyone.

Semaglutide administration (1-2 mg weekly) produces significant weight loss (median 13.3% at 6 months) in adults with obesity, with efficacy maintained even at lower maintenance doses (1 mg).

Semaglutide is a highly effective treatment for obesity, producing significant weight loss even at lower maintenance doses. It requires a weekly injection and is most effective when combined with lifestyle counseling. Patients should be aware of potential gastrointestinal side effects, which are usually mild.

Adjuvant semaglutide at lower doses (≤1 mg/week) achieves clinically significant weight loss (median 7.5% TWL) in post-bariatric surgery patients with refractory obesity, with a favorable side effect profile compared to higher doses.

If you have had bariatric surgery and are experiencing weight regain or insufficient loss, ask your doctor about adjuvant semaglutide. You may not need the highest dose (2.4 mg); many patients achieve significant weight loss (around 7.5% of total body weight) at lower doses (1 mg or less). This approach is often more affordable, has fewer side effects, and is sufficient for long-term management, especially if supply of higher doses is an issue.

Regular supervised walking significantly improves glycemic control (HbA1c) in type 2 diabetes patients, with supervised programs showing statistically significant benefits compared to non-supervised ones.

If you have Type 2 Diabetes, aim for at least 150 minutes of moderate walking per week, spread over at least three days. Supervised walking programs appear to offer better glycemic control than unsupervised efforts. If you cannot commit to long sessions, try breaking up long periods of sitting with short walks every 30 minutes.

Post-bariatric patients with insufficient weight loss or weight regain achieve significant additional weight loss and comorbidity improvement when treated with GLP-1 receptor agonists (semaglutide or dulaglutide).

If you have had bariatric surgery and are not losing enough weight or are gaining it back, ask your doctor about GLP-1 medications like semaglutide or dulaglutide. These drugs can help you lose more weight and improve health conditions like high blood pressure and sleep apnea. They are taken as weekly injections and are generally well-tolerated, though nausea is a common side effect.

Semaglutide (Ozempic) induces significant weight loss in obese patients primarily through appetite suppression and reduced energy intake, with efficacy directly correlated to dosage.

Semaglutide is an effective tool for weight loss, working by reducing hunger and calorie intake rather than burning more fat directly. It requires a weekly injection with a specific titration schedule to manage side effects like nausea. While effective, it is not a magic bullet; long-term safety data is still emerging, and it is contraindicated for people with certain thyroid or pancreatic histories.

Daily supplementation with 650 mg of a proprietary blend of Sphaeranthus indicus and Mangifera indica extracts (LI12542F6) for 56 days significantly increases muscle strength, endurance, and lean mass in young, recreationally active males undergoing resistance training.

If you are a young male who lifts weights regularly, taking 650 mg of this specific herbal blend (LI12542F6) daily for about 8 weeks, alongside your normal training, may help you lift heavier weights and last longer on cardio compared to taking a placebo. It also appeared to increase lean muscle mass and improve hormone profiles (higher testosterone, lower cortisol) without causing side effects in this study.